Group items tagged

IAM Healthcare and pharmacy labour activists have initiated a new worker empowerment project to help pharmacies unionise over unsafe staffing levels and increasing workloads. The campaign is coined "The Pharmacy Guild" to establish higher standards of practice in pharmacies to protect patients. The union issued a mission statement on Wednesday (8 November) highlighting three major demands and goals. They demanded that "staffing and workload standards should be set up to ensure safe patient care." There should be "representation and collective bargaining for pharmacy professionals in workplaces across the country."

After a month of intense talks, the British government and unions representing consultant doctors in England have reached an agreement, potentially ending six months of disruptive strike action. The Department of Health and Social Care (DHSC) has put forward an offer to reform the pay structure for senior doctors from January 2024, reducing the number of pay points and the time it takes to reach the top. As part of this offer, consultants will also be entitled to enhanced shared parental leave, bringing them in line with other NHS staff. New arrangements will ensure a clearer link between pay progression and evidence of skills, competencies and experience, the DHSC said. The British Medical Association (BMA) and Hospital Consultants and Specialists Association (HCSA) agreed to put the offer to their members for a vote in the coming weeks, with no further strike action to be called during that time.

The Pharmacists' Defence Association (PDA) has announced that it will support its member impacted by the decision to close 300 more Boots pharmacies. After the announcement of closure of 300 Boots pharmacies over the next year, the association believes this is approximately one out of every eight current Boots pharmacy locations. The company has insisted that the objective of this exercise is not to make existing pharmacist employees redundant, and they hope to be able to redeploy individuals into nearby alternative locations. However, PDA believes that it is unlikely that suitable alternative roles will be available for all and redundancy is a possibility for some. The PDA Union will provide pharmacists with information, support, and representation as part of the recognition agreement so that members are aware of and can exercise their rights at work. PDA officials will be in continued dialogue with the company throughout this closure programme.

In significant development, the Pharmacists' Defence Association (PDA) has advised its Boots members to challenge the "trustees' decision to end the ability to take an unreduced pension from age 60 by submitting complaints through the scheme's two-stage internal disputes procedure". The issue centers around the alterations made to pension scheme rules without the adequate disclosure to scheme members or their representatives. The PDA has drafted template letters to assist scheme members in response to undisclosed changes during a buyout process, sparking legal challenges and demands for transparency from Boots and scheme trustees. Paul Moloney, National Officer of the PDA Union leading the campaign, expressed concern over the sudden withdrawal of the right to an unreduced pension from age 60. "We have always maintained that members had a right under the rules to draw an unreduced pension from age 60," Moloney stated.

You're in the right place if you're looking for local businesses and professionals offering a wide variety of goods and services in Clintonville, WI. Save Local Now creates an unparalleled selection of banks & credit unions, car dealers, restaurants, hotels, doctors, contractors, day spas, medical centers, real estate agents, printing services, boutiques, social clubs and lot more. Search or browse our list of companies by selecting the category of your interest and get the complete business details, address, directions, website and phone numbers.

Save Local Now lists businesses for contractors, utilities, banks & credit unions, heating & air conditioning, insurance, community service, advertising, flowers & gifts, bars, employment agencies, apartments, car service and many more in Belleville IL 62220.

Stay connected with your favorite businesses, get best offerings, deals & updated with latest happening in Euclid, OH on Save Local Now. Shop locally and save money on wide range of products and services such as health and wellness, dental care, medical services, healthy habits, restaurants, food, golf, automotive services, non profit organization, insurance, banks and credit unions, telecommunications, graphic design, shopping, printing services, cleaning services and lot more. Get complete details about your favorite deals and share with your family and friends.

Aspen has committed not to charge more for its six generic cancer drugs for the next 10 years in the UK, according to the Competition and Markets Authority (CMA). The CMA also clarified that "although these commitments were offered while the UK was a part of the European Union" they remain "legally binding". It added: "The CMA has now assisted the NHS to secure binding undertakings from Aspen, under the law of England and Wales, which enshrine the UK elements of the commitments and are enforceable by UK courts, including in relation to the supply of these drugs in Northern Ireland and Scotland." This allows NHS to monitor and ensure compliance by Aspen following the UK's exit from the EU. In 2017, the European Commission began an investigation into Aspen over concerns that the company had engaged in excessive pricing for 6 off-patent cancer medicines.

The PDA has raised concerns over the 'deliberate breaches' of the NHS contract by some community pharmacy businesses, saying that it may cause harm to patients and damage the reputation of the profession. The organisation said concerned pharmacists have revealed to them that some businesses are now explicitly saying that if locums will not agree to work for less than a so-called 'maximum' hourly rate, the business will close the pharmacy for either part of, or the whole day. Some of these full or part-day closures are being communicated significantly in advance of the actual day, it added. The union further alleged that several pharmacy businesses seem to have simultaneously implemented identical so-called 'maximum rates' in what could be an anti-competitive behaviour.

The Indian government has suspended manufacturing in over 40 pharmaceutical companies based on a risk-based assessment conducted earlier in the year across 162 firms, according to the data provided by Union Health Minister Mansukh Mandaviya in Parliament on Thursday (Aug. 10). "Overall, a sum of 143 show-cause notices has been issued," Mandaviya said. There have been numerous recent incidents involving accusations from foreign countries regarding the contamination of syrups, eye drops, and ointments manufactured in India. Countries such as the Gambia, Uzbekistan, and Cameroon have linked the deaths of 70, 18, and six children, respectively, to cough syrups contaminated in India. Licenses for specific products have been either temporarily suspended or fully revoked for an additional 66 companies. In one case, an FIR has been registered, and in 21 cases, warning letters have been issued following inspections by both the Central Drugs Standard Control Organization and State authorities, the Minister added. Meanwhile, the Indian government has mandated rigorous testing for cough syrups before export. Starting June 1, any cough syrup must possess a government laboratory-issued certificate of analysis before being exported, the government said in a notice dated May 22.

The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute migraines in adults with or without aura. However, there is a caveat. This recommendation applies exclusively to individuals with a prior history of migraines, meeting one of the following criteria: At least 2 triptans were tried and they did not work well enough or Triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough. This drug was developed by the US-based Biohaven Pharmaceuticals, acquired by Pfizer in 2022, in an $11.6 billion deal. Nurtec ODT is the commercial name for the drug in the US, while the European Union approved the drug under the name Vydura in April 2022. NICE recommended rimegepant, an oral lyophilisate (dissolving wafer) and the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment, to be taken at the onset of a migraine attack. Migraine affects one in seven people in the UK, often with a debilitating impact, Pfizer UK said in a statement. The condition entails symptoms such as head pain, vomiting, nausea, altered vision, fatigue, and heightened sensitivity to light, sound, and odours.

Proposed changes to a European Union pharmaceuticals law will include stronger obligations for the supply of medicines and earlier notifications of shortages, EU Health Commissioner Stella Kyriakides said last week (January 17). Kyriakides told a session of the European Parliament that shortages of antibiotics are a growing problem for many European countries. She said the European Commission's proposal to revise the pharmaceuticals legislation is planned for March. "Our objective is and remains to secure access to medicines for all patients in need and to avoid any market disruption of medicines in the EU," Kyriakides said. Shortages of antibiotics have been reported in 26 European countries, the European Medicines Agency says. The unseasonably early upsurge in respiratory infections in Europe this winter and insufficient production capacity are the root causes of the shortages, Kyriakides said. Numerous EU lawmakers speaking at the session said the shortages needed to be tackled urgently. But experts say shortages of essential generic medicines like antibiotics are likely to be recurrent in Europe due to problems in the sector such as the gradual migration of generic manufacturing to Asia.

Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta. Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals, allowing importing, exporting, wholesaling and trading abroad. Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection by the Malta Medicines Authority. The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater flexibility in how the business manages the flow of medicines across its territories. These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale and productivity.

The Royal Pharmaceutical Society (RPS) has called pharmacy employers and pharmacy trade unions to come together to a round table meeting to agree on principles for a way forward that ensures patients benefit consistently from access to high quality, adequately staffed, safe pharmacy services. It has also urged the governments, NHS organisations and individual pharmacy teams to define clear prioritisation plans, which can be embedded in organisational business continuity plans which set out the pharmacy services that are essential and must always be provided and can be de-prioritised at specific levels of pressures. The challenges for pharmacies are compounded by the escalating cost of living crisis. With unprecedented levels of burnout among pharmacists, pharmacy closures and the potential for strike action, RPS has called for three things- 'professionalism, respect and prioritisation.'

The Pharmacists' Defence Association (PDA) has welcomed the Westminster government's move to backtracked from their plan to remove a large number of rights and standards and is having to overhaul the Retained EU Law Bill. This had included a number of employment rights, including TUPE transfers and the Working Time Directive, which had been established in the UK from EU law. The Bill's 'sunset clause' was originally going to automatically repeal any EU law not enshrined in UK law by the end of 2023. Critics of the Bill were concerned that this gave the government powers to reform or remove laws without normal Parliamentary scrutiny. "This would have abolished many improvements to workers' rights which were enacted through the EU legislature," said PDA.

The Royal Pharmaceutical Society (RPS) and Pharmacist Support hosted a roundtable on the impact of pharmacy workforce wellbeing on patient safety on Wednesday (17 May). It also released its annual Workforce Wellbeing Survey which showed continued pressures on pharmacy teams. The discussion explored the actions needed to support staff so they can continue providing safe and effective patient care and included representatives from the NHS, professional bodies, employers, trade unions, education and regulators. A report of the roundtable will be published in the summer. Amandeep Doll, RPS Head of Professional Belonging, said: "We know that pharmacy teams go above and beyond for their patients, but are also under enormous pressure. "Now more than ever, we need to strive to make the pharmacy profession more inclusive and ensure that everyone's wellbeing is supported. "It is vital that we do all we can to encourage people into pharmacy and to support them so they can enhance their skills, develop their careers, and continue to deliver high-quality patient care. "This discussion was a welcome step and showed that making a difference for staff wellbeing requires a concerted effort from stakeholders across the whole of pharmacy.

Fife-based trainee pharmacist and Honorary Secretary of the PDA LGBT+ Network, Soh Xi Ken has won the Scottish Trades Union Congress' (STUC) Equality Award. One of Scotland's leading LGBT+ campaigners and Honorary Secretary of the PDA's LGBT+ Network has been recognised for his advocacy work for LGBT+ pharmacists in Scotland. Soh Xi Ken of the PDA received the Equality Award at the STUC Annual Congress in April 2023 in Dundee. The award praised Xi Ken's tireless advocacy for LGBT+ workers within pharmacies in Scotland, highlighting his personal experience of homophobia in Scotland and his home country, Malaysia. In May 2021, Xi Ken became a founding member of the PDA LGBT+ Network's committee and was elected as their first Honorary Secretary. The PDA LGBT+ Network is the first of its kind in the pharmacy world and has made a significant difference to the profile of LGBT+ people in the profession. Xi Ken and others within the PDA LGBT+ Network spotted that there was a lack of LGBT+-specific guidance given to pharmacy students and that their unique and specific health needs were not being addressed as part of the pharmacy education that they received.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

Boots UK will offer a staring salary of £42,000 per annum to newly qualified pharmacists joining the pharmacy chain. The company also revealed that "in addition, any existing pharmacists in the bargaining unit currently receiving less than £43k." The newly announced hike in the salary - following an agreement reached between the multiple and and the Pharmacist Defence Association - will be effective from 1 August 2022. "This enhanced offer for Newly Qualified Pharmacists and further investment in those in the early stages of their careers at Boots is a key part of our commitments to pharmacists," the company said. Boots and PDA Union also announced in a joint statement that they will conduct a further formal review of all pharmacists' pay in accordance with the collective agreement, effective from 1 November 2022.

LloydsPharmacy has offered three per cent increase in base pay backdated to 1 April for its store pharmacists, the union of Pharmacists' Defence Association (PDAU) who represented them has announced. "We are pleased to announce that following a consultation of its members, the PDAU has informed the company that agreement can be reached on the company's latest offer, made in July 2022," said the PDAU. The offer made by the company also includes introduction of an overtime rate of 1.5 times basic pay for each hour worked after contracted hours. This will run for a trial period and be reviewed as part of the next pay round. "All pharmacists will receive an initial £1,000 payment under the proposed LTIP scheme, paid in April 2024. This will be to all in the bargaining unit and will not be dependent on meeting any criteria such as targets," said PDAU.